Antiepileptic; increases levels of γ-aminobutyric acid (GABA) in the brain. Prepn: B. S. Burton, Am. Chem. J. 3, 385 (1882); E. Oberreit, Ber. 29, 1998 (1896); M. Tiffeneau, Y. Deux, Compt. Rend. 212, 105 (1941). LC-MS/MS determn in plasma: D. S. Jain et al., Talanta 72, 80 (2007). Anticonvulsant activity: H. Meunier et al., Therapie 18, 435 (1963). Comprehensive description: Z. L. Chang, Anal. Profiles Drug Subs. 8, 529-556 (1979). Review of teratogenicity studies: H. Nau et al., Pharmacol. Toxicol. 69, 310-321 (1991); R. Alsdorf, D. F. Wyszynski, Expert Opin. Drug Saf. 4, 345-353 (2005). Review of pharmacology and clinical experience in epilepsy: E. M. Rimmer, A. Richens, Pharmacotherapy 5, 171-184 (1985); in psychiatric disease: D. R. P. Guay, ibid. 15, 631-647 (1995); in migraine prophylaxis: C. E. Shelton, J. F. Connelly, Ann. Pharmacother. 30, 865-866 (1996). Review of pharmacodynamics and mechanisms of action: W. Lscher, Prog. Neurobiol. 58, 31-59 (1999).
Anticonvulsant; antimanic; antimigraine.
Anticonvulsant; Antimigraine; Antimanic